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Abstract
Background
An elevated level of serum uric acid (SUA) is associated with an increased risk of cardiovas-
cular disease. Pharmacological intervention with urate-lowering agents, such as the con-
ventional purine analogue xanthine oxidase (XO) inhibitor, allopurinol, has been used widely
for a long period of time in clinical practice to reduce SUA levels. Febuxostat, a novel non-
purine selective inhibitor of XO, has higher potency for inhibition of XO activity and greater
urate-lowering efficacy than conventional allopurinol. However, clinical evidence regarding
the effects of febuxostat on atherosclerosis is lacking. The purpose of the study was to test
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whether treatment with febuxostat delays carotid intima-media thickness (IMT) progression
in patients with asymptomatic hyperuricemia.
Methods and findings
The study was a multicenter, prospective, randomized, open-label, blinded-endpoint clinical
trial undertaken at 48 sites throughout Japan between May 2014 and August 2018. Adults
with both asymptomatic hyperuricemia (SUA >7.0 mg/dL) and maximum IMT of the com-
mon carotid artery (CCA)�1.1 mm at screening were allocated equally using a central web
system to receive either dose-titrated febuxostat (10–60 mg daily) or as a control-arm, non-
pharmacological lifestyle modification for hyperuricemia, such as a healthy diet and exercise
therapy. Of the 514 enrolled participants, 31 were excluded from the analysis, with the
remaining 483 people (mean age 69.1 years [standard deviation 10.4 years], female 19.7%)
included in the primary analysis (febuxostat group, 239; control group, 244), based on a
modified intention-to-treat principal. The carotid IMT images were recorded by a single
sonographer at each site and read in a treatment-blinded manner by a single analyzer at a
central core laboratory. The primary endpoint was the percentage change from baseline to
24 months in mean IMT of the CCA, determined by analysis of covariance using the alloca-
tion adjustment factors (age, gender, history of type 2 diabetes, baseline SUA, and baseline
maximum IMT of the CCA) as the covariates. Key secondary endpoints included changes in
other carotid ultrasonographic parameters and SUA and the incidence of clinical events.
The mean values (± standard deviation) of CCA-IMT were 0.825 mm ± 0.173 mm in the
febuxostat group and 0.832 mm ± 0.175 mm in the control group (mean between-group dif-
ference [febuxostat − control], −0.007 mm [95% confidence interval (CI) −0.039 mm to
0.024 mm; P = 0.65]) at baseline; 0.832 mm ± 0.182 mm in the febuxostat group and 0.848
mm ± 0.176 mm in the control group (mean between-group difference, −0.016 mm [95% CI
−0.051 mm to 0.019 mm; P = 0.37]) at 24 months. Compared with the control group, febuxo-
stat had no significant effect on the primary endpoint (mean percentage change 1.2% [95%
CI −0.6% to 3.0%] in the febuxostat group (n = 207) versus 1.4% [95% CI −0.5% to 3.3%] in
the control group (n = 193); mean between-group difference, −0.2% [95% CI −2.3% to
1.9%; P = 0.83]). Febuxostat also had no effect on the other carotid ultrasonographic param-
eters. The mean baseline values of SUA were comparable between the two groups (febuxo-
stat, 7.76 mg/dL ± 0.98 mg/dL versus control, 7.73 mg/dL ± 1.04 mg/dL; mean between-
group difference, 0.03 mg/dL [95% CI −0.15 mg/dL to 0.21 mg/dL; P = 0.75]). The mean
value of SUA at 24 months was significantly lower in the febuxostat group than in the control
group (febuxostat, 4.66 mg/dL ± 1.27 mg/dL versus control, 7.28 mg/dL ± 1.27 mg/dL; mean
between-group difference, −2.62 mg/dL [95% CI −2.86 mg/dL to −2.38 mg/dL; P < 0.001]).
Episodes of gout arthritis occurred only in the control group (4 patients [1.6%]). There were
three deaths in the febuxostat group and seven in the control group during follow-up. A limi-
tation of the study was the study design, as it was not a placebo-controlled trial, had a rela-
tively small sample size and a short intervention period, and only enrolled Japanese
patients with asymptomatic hyperuricemia.
Conclusions
In Japanese patients with asymptomatic hyperuricemia, 24 months of febuxostat treatment
did not delay carotid atherosclerosis progression, compared with non-pharmacological
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care. These findings do not support the use of febuxostat for delaying carotid atherosclero-
sis in this population.
Trial registration
University Hospital Medical Information Network Clinical Trial Registry UMIN000012911.
Author summary
Why was this study done?
• Elevated levels of serum uric acid (SUA) increase the risk of gout and may be associated
with the risk of developing cardiometabolic disorders and subsequent cardiovascular
disease.
• Translational research suggests that urate-lowering therapy by inhibition of xanthine
oxidase (XO) may attenuate experimental atherosclerosis. However, the clinical effects
of XO inhibitors on atherosclerosis in patients with asymptomatic hyperuricemia
remain uncertain.
• Carotid intima-media thickness (IMT) measurement is a simple and noninvasive
method to monitor atherosclerosis. We therefore investigated whether treatment with
febuxostat, a non-purine selective inhibitor of XO, delayed the progression of carotid
atherosclerosis compared to non-pharmacological care for hyperuricemia in this patient
population.
What did the researchers do and find?
• The study was a multicenter, prospective, randomized, open-label, blinded-endpoint
clinical trial on 483 eligible participants (mean age 69.1 [standard deviation 10.4],
female 19.7%) with asymptomatic hyperuricemia (SUA >7.0 mg/dL) and maximum
IMT of the common carotid artery�1.1 mm. The results showed that there was no sig-
nificant difference between febuxostat and non-pharmacological care for hyperuricemia
in the progression of carotid atherosclerosis assessed by IMT over 24 months of follow-
up.
• Febuxostat treatment was well tolerated and did not increase the incidence of cardiovas-
cular and all-cause mortality.
What do these findings mean?
• Our findings do not support the use of febuxostat to delay carotid atherosclerosis in
patients with asymptomatic hyperuricemia.
• Further research is needed to determine the effects of febuxostat on atherosclerosis and
cardiovascular safety in patients with hyperuricemia irrespective of the presence of gout.
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Introduction
An elevated level of serum uric acid (SUA) may be associated with cardiometabolic abnormali-
ties, including hypertension and insulin resistance, potentially leading to the development of
atherosclerosis and resultant cardiovascular disease (CVD) [1–3]. Thus, hyperuricemia is con-
sidered a residual risk factor for CVD [4], and whether urate-lowering therapy can attenuate
atherosclerosis and improve prognosis is an important clinical issue.
Pharmacological intervention with urate-lowering agents, such as allopurinol, a conven-
tional purine analogue xanthine oxidase (XO) inhibitor, has been used widely for a long period
of time in clinical practice to prevent the development of gout and reduce SUA levels. XO is an
enzyme responsible for catalyzing the final step in the conversion of purine to uric acid. Its
action produces excess reactive oxygen species that can play a detrimental role in the patho-
genesis of atherosclerosis [5,6]. To date, experimental studies in apolipoprotein E knockout
mice fed a Western-type diet [7,8] have demonstrated that XO inhibition improved endothe-
lial function and attenuated experimental atherosclerosis by suppressing excess production of
oxidative stress.
Febuxostat, a novel non-purine selective inhibitor of XO, has been approved for the treat-
ment of hyperuricemia and gout. Febuxostat is known to have greater potency for inhibition
of XO activity and more urate-lowering efficacy than conventional allopurinol [9,10]. Accord-
ingly, febuxostat may have superior anti-oxidative and anti-atherogenic effects to allopurinol
[7,11]. However, in the recent CARES trial that enrolled patients with gout and documented
CVD, febuxostat was noninferior to allopurinol with respect to the incidence of composite CV
events, including atherosclerosis-related coronary and cerebral events [12]. Thus, it is still con-
troversial whether febuxostat can exert a beneficial impact on atherosclerosis and relevant
CVD in clinical settings [13].
We herein report the findings of a long-term, multicenter, randomized clinical study that
investigated the effects of febuxostat on atherosclerosis in Japanese patients with hyperurice-




The PRIZE (program of vascular evaluation under uric acid control by xanthine oxidase inhib-
itor, febuxostat: multicenter, randomized controlled) study was a multicenter, prospective,
randomized, open-label, blinded-endpoint clinical trial. After trial registration was completed
in January 2014 (University Hospital Medical Information Network Clinical Trial Registry
UMIN000012911 [https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=
R000015081]), trial recruitment was carried out between May 2014 and August 2018 at 48 clin-
ical sites throughout Japan.
The study protocol was approved by the local institutional review boards and independent
ethics committees at all sites. The trial was conducted in full compliance with the Declaration
of Helsinki and according to the Ethical Guidelines for Medical and Health Research Involving
Human Subjects established by the Ministry of Health, Labour, and Welfare and Ministry of
Education, Culture, Sports, Science, and Technology in Japan. Prior to enrollment, all partici-
pants received an adequate explanation of the study plan and provided written informed con-
sent. The study is reported according to the CONSORT guidelines (S1 CONSORT Checklist).
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The maximum IMT of the common carotid artery (CCA) was measured prior to randomi-
zation to assess eligibility. After eligibility was confirmed and the medical background
reviewed, the patients were randomized equally to either a febuxostat group (10–60 mg daily)
or a control group (non-pharmacological treatment of hyperuricemia). All patients were fol-
lowed up with study visits scheduled at 1, 2, 3, 6, 12, and 24 months after the baseline visit.
Carotid artery ultrasonography was performed at baseline and after 12 and 24 months (or at
premature termination) at each local site. The full protocol appears in S1 Text, and the details
of the study rationale and design have been described previously [14].
Study participants
The inclusion and exclusion criteria for the study are listed in S1 Table. Individuals eligible for
the study were adults (aged�20 years) who had asymptomatic hyperuricemia with an SUA
>7.0 mg/dL and a maximum CCA-IMT�1.1 mm measured at eligibility assessment, defined
as a carotid arterial plaque (localized protruding lesion) in accordance with the guidelines of
the Japan Society of Ultrasonic in Medicine and the Japan Academy of Neurosonology [15].
Key exclusion criteria were the administration of any SUA-lowering agents within the 8-week
period prior to assessment of eligibility, the presence of gouty tophus, or symptoms of gout
arthritis within one year before assessment of eligibility.
Randomization and treatment
Patients were randomized to a febuxostat group or control group in a 1:1 ratio at the automatic
web-based PRIZE Data Center. The randomization was performed using a modified minimi-
zation method with a biased-coin assignment balanced for age (<65,�65 years), gender, pres-
ence or absence of type 2 diabetes, SUA (<8.0,�8.0 mg/dL), and maximum CCA-IMT (<1.3,
�1.3 mm).
All participants in both groups received an appropriate lifestyle modification for hyperuri-
cemia, such as healthy diet and exercise therapy, and the modification was continued during
the study period. Based on the protocol, patients assigned to the febuxostat group received an
initial dose of 10 mg daily that was titrated to 20 mg daily at 1 month and 40 mg daily at 2
months. Febuxostat 40 mg daily was targeted as the maintenance dose, but at 3 months or
later, the dose of febuxostat could be increased to 60 mg daily. If SUA levels decreased to�2.0
mg/dL during the study period, the maintenance dose was decreased by 20 mg.
Each participant’s background treatment, such as antidiabetic agents, antiplatelet agents,
antihypertensive agents, and lipid-lowering agents, was unchanged during the study period if
possible, based on the patient’s clinical condition.
Study endpoints
The primary endpoint of the study was the percentage change in the mean IMT of the CCA
from baseline to 24 months.
The secondary endpoints included the following: (1) The values and changes from baseline
at 12 and 24 months in the mean and maximum IMT of the CCA (except for the primary end-
point), bulb, and the internal carotid artery (ICA), and the plaque area and plaque grayscale
median; (2) the values and changes from baseline in SUA at 6, 12, and 24 months; (3) the val-
ues and changes from baseline in vital signs and laboratory measurements; (4) the incidence of
prespecified composite and individual clinical events (S2 Text), consisting of cardiovascular
death, nonfatal myocardial infarction and stroke, renal events (doubling of serum creatinine,
initiation of renal replacement therapy, or renal transplantation), and all-cause death; and (5)
adverse events during the study period.
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Measurement of carotid IMT
The protocol and method for measuring carotid IMT have been described in detail previously
[14,16]. According to the testing manual (S3 Text), based on the standardized protocol [17],
high-resolution carotid ultrasonography using a standard system equipped with a>7.5-MHz
linear transducer was performed at each site in a blinded manner by an expert, trained sonog-
rapher who had attended a lecture on acquiring images of the carotid IMT. All the imaging
data were stored as JPEG files and then sent to the core imaging laboratory, where an expert
analyzer measured the IMT values in a blinded manner using an automated IMT measure-
ment software program (Vascular Research Tools 5, Medical Imaging Applications LLC, Cor-
alville, IA) [18].
To measure mean CCA-IMT, longitudinal B-mode images of each CCA were obtained,
and mean IMT of the CCA was determined at the continuous region 10 mm proximal to the
origin of the bulb at the far wall using an auto-tracing system. Maximum CCA-IMT was
defined as the maximum IMT measured at the near and far walls in the scanned CCA areas.
The mean and maximum IMT values on the left and right sides were averaged at baseline and
at 12 and 24 months. The absolute and percentage changes from baseline at 12 and 24 months
were calculated for each side and then averaged. The following IMTs were also measured in a
similar manner: mean and maximum IMTs of the bulb and ICA. Plaque was defined as a focal
region with an IMT�1.1 mm that protruded into the lumen and was distinct from the adja-
cent boundary [15], and the plaque area with the lowest echogenicity and its median gray scale
were also measured automatically [19].
Power calculation
The sample size was calculated based on the following assumptions: a 1.6% between-group dif-
ference in the primary endpoint 24 months after baseline [16,20], a standard deviation (SD) of
6.0% for individual differences, and 80% detection power for a two-tailed, two-sample t test at
a significance level of 0.05. The sample size was set at 250 patients in each group, with anticipa-
tion of a 10% dropout rate.
Statistical analysis
The full statistical analysis plan appears in S4 Text. The data for the primary and secondary
endpoints were collected at each time point. All the efficacy analyses were conducted in a mod-
ified intention-to-treat manner, including all randomized subjects who were not lost to follow-
up. For the baseline variables, the summary statistics were expressed as frequencies and pro-
portions for categorical data and mean (SD) or median (interquartile range) for continuous
variables.
For the primary analysis, the mean percentage change in the mean CCA-IMT from baseline
to 24 months and its 95% confidence interval (CI), estimated by analysis of covariance
(ANCOVA) using the allocation adjustment factors as covariates, was compared between the
treatment groups. Analysis of the primary endpoint was also done in subgroups stratified by
the allocation and prespecified factors. Although we did not impute missing data for the pri-
mary analysis, a sensitivity analysis using a mixed-effects model for repeated measures
(MMRM) was performed to examine the effect of these missing data. Comparisons of changes
in the other efficacy endpoints between the treatment groups were performed with a Student
unpaired t test.
All P values were two-sided with a level of significance of 0.05, and there were no adjust-
ments for multiple comparisons. All statistical analyses were performed using SAS software
version 9.4.
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Results
Description of patients and interventions
Between May 2014 and Jun 2016, 514 patients were registered in the study and assigned ran-
domly to either the febuxostat group (n = 257) or the control group (n = 257) (Fig 1). A total
of 31 patients (febuxostat, 18 patients; control, 13 patients) were lost to follow-up because of
either duplicate registration, voluntary withdrawal, no visit after randomization, or protocol
deviation. The study was completed by 86.0% of febuxostat-treated and 82.9% of control
patients. Within the modified intention-to-treat population (full analysis set: febuxostat, 239
patients; control, 244 patients), 207 patients (86.6%) in the febuxostat group and 193 patients
(79.1%) in the control group were included in the analysis of the primary endpoint. Table 1
shows the baseline demographics and clinical characteristics of the full analysis population,
and it appeared that the groups were well matched.
In the febuxostat group, 33.9% of the patients received 10 mg, 23.5% received 20 mg, 2.3%
received 30 mg, 29.4% received 40 mg, and 5.0% received 60 mg daily as the final adjusted
dose of febuxostat (S1 Fig). The mean febuxostat daily dose was 22.8 (SD 15.9) mg at 24
months or termination for the full analysis set and 24.5 (SD 15.2) mg at 24 months or termina-
tion in those patients who remained on febuxostat until the end of the study.
Carotid IMT
The baseline mean CCA-IMT values were 0.825 (SD 0.173) mm and 0.832 (SD 0.175) mm in
the febuxostat and control groups, respectively. The absolute values and changes from baseline
were comparable between the treatment groups at both 12 and 24 months (Table 2). For the
primary endpoint, the allocation factors-adjusted mean percentage changes were 1.2% (95%
CI −0.6% to 3.0%) in the febuxostat group and 1.4% (95% CI −0.5% to 3.3%) in the control
group, with a mean between-group difference (febuxostat − control) −0.2% (95% CI −2.3% to
1.9%; P = 0.83). No significant difference was observed in the sensitivity analysis using the
MMRM (S2 Table). Subgroup analyses showed febuxostat had an inconsistent effect without
significant heterogeneity on the primary endpoint in the subgroups (Fig 2). However, in the
febuxostat-treated patients, the subgroups with a SUA�8.0 mg/dL at baseline or those who
received antiplatelet agents showed a tendency to have a reduction in the primary endpoint.
Additional subgroup analyses in patients with an estimated glomerular filtration rate (eGFR)
�60 mL/min/1.73 m2 at baseline also showed that the subgroup taking febuxostat with a
higher SUA level (>8.0 mg/dL) tended to have a greater percentage change in mean
CCA-IMT, although the difference between the two groups was not statistically significant (S2
Fig). Other carotid ultrasonographic values and their changes from baseline also did not differ
between the treatment groups at any time point (Table 2).
Effects on laboratory parameters (S3 Table)
At baseline, the SUA levels were 7.76 (SD 0.98) mg/dL and 7.73 (SD 1.04) mg/dL in the febuxo-
stat and control groups, respectively. There were significant differences in the SUA levels
between the treatment groups at 6, 12, and 24 months, and the final SUA levels were 4.66 (SD
1.27) mg/dL and 7.28 (SD 1.27) mg/dL in the febuxostat and control groups, respectively (Fig
3). The absolute reductions in SUA from baseline in the febuxostat group were also signifi-
cantly greater than those in the control group at 6, 12, and 24 months.
Mean baseline systolic blood pressures were 128.9 (SD 14.7) mm Hg and 127.0 (SD 15.7)
mm Hg in the febuxostat and control groups, respectively. Although a significant between-
group difference in the absolute change from baseline in systolic blood pressure was observed
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at 12 months, there was no significant difference at 24 months. There were no significant
between-group differences in the values and changes from baseline at 12 and 24 months in dia-
stolic blood pressure and body mass index. In addition, there were no significant between-
group differences in the values and changes from baseline at 12 and 24 months in the labora-
tory parameters.
Adjudicated clinical events and adverse events
Information was collected from the safety analysis of those patients who had data collected fol-
lowing randomization (febuxostat, 241 patients; control, 247 patients). Table 3 summarizes
the number of patients with adjudicated clinical events. Overall, a numerically lower incidence
of clinical events was observed in the febuxostat group compared with the control group. One
cardiovascular death and three all-cause deaths occurred in the febuxostat group, whereas
there were three cardiovascular deaths and seven all-cause deaths in the control group.
A summary of the adverse events reported by the local investigators is shown in S4 Table.
Overall, 52 patients (21.6%) had one or more adverse events (total 88 events) in the febuxostat
group and 48 patients (19.4%) had them (83 events) in the control group. No gout arthritis
occurred in the febuxostat group, whereas four patients (1.6%) developed gout arthritis in the
control group. Impaired liver function and skin eruption were more common in the febuxostat
Fig 1. Flow of patients in the PRIZE study. IMT, intima-media thickness.
https://doi.org/10.1371/journal.pmed.1003095.g001
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group. Individual adverse events reported from the local investigators are listed in S5 Table. In
the febuxostat group, 19 patients (7.9%) had adverse events that may have been caused by
febuxostat administration. In these 19 patients, 11 discontinued febuxostat permanently, three
discontinued it temporarily, and two decreased the dose.
Discussion
Main findings
The main finding of this multicenter, randomized study was that 24 months of febuxostat
treatment did not delay carotid IMT progression compared with non-pharmacological lifestyle
Table 1. Baseline demographics and clinical characteristics.
Variable Febuxostat (n = 239) Control (n = 244)
Sex, number (%)
Women 49 (20.5) 46 (18.9)
Men 190 (79.5) 198 (81.1)
Age, year
Mean (SD) 69.1 (10.1) 69.1 (10.7)
Median (IQR) 70 (63–76) 71 (63–78)
BMI, mean (SD), kg/m2 24.8 (3.9) 25.0 (3.5)
Current smoker, number (%) 28 (11.7) 24 (9.8)
Blood pressure, mean (SD), mm Hg
Systolic 128.9 (14.7) 127.0 (15.7)
Diastolic 73.3 (11.6) 74.2 (11.4)
Medical history, number (%)
Hypertension 212 (88.7) 217 (88.9)
Diabetes 85 (35.6) 88 (36.1)
Dyslipidemia 144 (60.3) 145 (59.4)
Previous gouty arthritis 6 (2.5) 4 (1.6)
Myocardial infarction 34 (14.2) 26 (10.7)
PCI 32 (13.4) 37 (15.2)
CABG 12 (5.0) 13 (5.3)
Stroke 14 (5.9) 12 (4.9)
Heart failurea 41 (17.2) 39 (16.0)
Prior medication, number (%)
Any antihypertensive agent 217 (90.8) 222 (91.0)
Renin-angiotensin system inhibitorb 156 (65.3) 167 (68.4)
Calcium channel blocker 132 (55.2) 122 (50.0)
β-Blocker 86 (36.0) 96 (39.3)
Diuretic 70 (29.3) 70 (28.7)
Any lipid-reducing agent 126 (52.7) 129 (52.9)
Statins 115 (48.1) 124 (50.8)
Ezetimibe 10 (4.2) 6 (2.5)
Any antiplatelet agent 96 (40.2) 108 (44.3)
Aspirin 77 (32.2) 88 (36.1)
aInvestigator reported.
bAngiotensin converting enzyme inhibitor or angiotensin receptor blocker.
Abbreviations: BMI, body mass index; CABG, coronary artery bypass grafting; IQR, interquartile range; PCI,
percutaneous coronary intervention
https://doi.org/10.1371/journal.pmed.1003095.t001
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Table 2. Changes in carotid ultrasonography parameters.
Endpoint Time point Febuxostat Control Group difference (95% CI) P Value
Number Mean (SD) Number Mean (SD)
Mean CCA-IMT, mm Baseline 239 0.825 (0.173) 241 0.832 (0.175) −0.007 (−0.039 to 0.024) 0.65
12 months 207 0.826 (0.185) 210 0.841 (0.188) −0.015 (−0.051 to 0.021) 0.42
24 months 208 0.832 (0.182) 196 0.848 (0.176) −0.016 (−0.051 to 0.019) 0.37
Delta from baseline, mm 12 months 207 0.003 (0.099) 208 0.012 (0.090) −0.009 (−0.027 to 0.010) 0.35
24 months 207 0.006 (0.087) 193 0.008 (0.090) −0.002 (−0.020 to 0.015) 0.81
Percentage change from baseline 12 months 207 0.011 (0.115) 208 0.021 (0.110) −0.010 (−0.032 to 0.011) 0.35
24 months 207 0.015 (0.104) 193 0.018 (0.109) −0.003 (−0.024 to 0.018) 0.81
Mean bulb-IMT, mm Baseline 225 1.068 (0.342) 222 1.085 (0.364) −0.017 (−0.083 to 0.048) 0.61
12 months 194 1.062 (0.325) 196 1.089 (0.354) −0.027 (−0.094 to 0.041) 0.44
24 months 190 1.131 (0.380) 181 1.136 (0.384) −0.005 (−0.083 to 0.073) 0.89
Delta from baseline, mm 12 months 185 −0.001 (0.263) 179 0.009 (0.258) −0.010 (−0.064 to 0.044) 0.71
24 months 178 0.065 (0.272) 169 0.030 (0.279) 0.036 (−0.023 to 0.094) 0.23
Percentage change from baseline 12 months 185 0.044 (0.230) 179 0.050 (0.244) −0.006 (−0.055 to 0.043) 0.81
24 months 178 0.104 (0.272) 169 0.064 (0.230) 0.041 (−0.013 to 0.094) 0.13
Mean ICA-IMT, mm Baseline 145 0.789 (0.297) 155 0.773 (0.328) 0.016 (−0.055 to 0.087) 0.66
12 months 154 0.840 (0.348) 139 0.822 (0.371) 0.017 (−0.066 to 0.101) 0.68
24 months 134 0.846 (0.364) 126 0.848 (0.346) −0.001 (−0.088 to 0.085) 0.98
Delta from baseline, mm 12 months 111 0.024 (0.233) 111 0.024 (0.345) −0.0002 (−0.078 to 0.078) >0.99
24 months 102 0071 (0.268) 101 0.115 (0.276) −0.044 (−0.119 to 0.031) 0.25
Percentage change from baseline 12 months 111 0.070 (0.273) 111 0.083 (0.315) −0.013 (−0.091 to 0.065) 0.75
24 months 102 0.136 (0.354) 101 0.179 (0.350) −0.043 (−0.141 to 0.054) 0.38
Maximum CCA-IMT, mm Baseline 239 1.040 (0.230) 241 1.056 (0.235) −0.016 (−0.057 to 0.026) 0.46
12 months 207 1.045 (0.254) 210 1.071 (0.264) −0.025 (−0.075 to 0.024) 0.32
24 months 208 1.044 (0.244) 197 1.070 (0.250) −0.026 (−0.074 to 0.022) 0.29
Delta from baseline, mm 12 months 207 0.013 (0.159) 208 0.016 (0.151) −0.003 (−0.033 to 0.027) 0.84
24 months 207 0.003 (0.140) 194 0.008 (0.146) −0.006 (−0.034 to 0.023) 0.70
Percentage change from baseline 12 months 207 0.020 (0.145) 208 0.025 (0.135) −0.005 (−0.032 to 0.022) 0.74
24 months 207 0.015 (0.132) 194 0.019 (0.133) −0.004 (−0.030 to 0.022) 0.76
Maximum bulb-IMT, mm Baseline 225 1.533 (0.518) 222 1.578 (0.604) −0.045 (−0.150 to 0.060) 0.40
12 months 194 1.591 (0.521) 196 1.633 (0.583) −0.042 (−0.152 to 0.068) 0.45
24 months 190 1.702 (0.628) 181 1.683 (0.621) 0.019 (−0.109 to 0.147) 0.77
Delta from baseline, mm 12 months 185 0.077 (0.458) 179 0.068 (0.476) 0.009 (−0.088 to 0.105) 0.86
24 months 178 0.168 (0.470) 169 0.083 (0.485) 0.085 (−0.016 to 0.186) 0.098
Percentage change from baseline 12 months 185 0.119 (0.312) 179 0.107 (0.312) 0.012 (−0.052 to 0.076) 0.71
24 months 178 0.171 (0.324) 169 0.112 (0.299) 0.059 (−0.007 to 0.125) 0.079
Maximum ICA-IMT, mm Baseline 145 1.058 (0.380) 155 1.050 (0.457) 0.008 (−0.087 to 0.104) 0.86
12 months 154 1.197 (0.521) 139 1.167 (0.559) 0.031 (−0.094 to 0.155) 0.63
24 months 134 1.156 (0.526) 126 1.177 (0.551) −0.021 (−0.153 to 0.111) 0.75
Delta from baseline, mm 12 months 111 0.080 (0.426) 111 0.074 (0.480) 0.006 (−0.114 to 0.126) 0.92
24 months 102 0.098 (0.396) 101 0.187 (0.478) −0.088 (−0.210 to 0.033) 0.15
Percentage change from baseline 12 months 111 0.128 (0.407) 111 0.134 (0.392) −0.006 (−0.112 to 0.100) 0.91
24 months 102 0.140 (0.371) 101 0.215 (0.447) −0.075 (−0.189 to 0.039) 0.20
Plaque area, mm2 Baseline 203 7.176 (5.027) 194 6.874 (6.627) 0.302 (−0.863 to 1.467) 0.61
12 months 85 7.971 (5.206) 91 8.248 (7.419) −0.277 (−2.175 to 1.621) 0.77
24 months 79 8.885 (5.665) 89 7.551 (7.109) 1.334 (−0.615 to 3.283) 0.18
(Continued)
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modification in Japanese patients with asymptomatic hyperuricemia, despite a significant dif-
ference in SUA levels between the groups. Febuxostat treatment was tolerable and did not
increase the incidence of CVD and mortality in this population.
XO inhibition and atherosclerosis
To our knowledge, this is the first randomized trial that has investigated whether or not lower-
ing SUA concentrations using febuxostat delays the progression of carotid atherosclerosis in
patients with asymptomatic hyperuricemia. To date, two randomized trials reported that
short- and long-term treatment with a conventional XO inhibitor, allopurinol, could attenuate
carotid IMT progression in patients with type 2 diabetes and asymptomatic hyperuricemia,
and in patients with recent ischemic stroke or transient ischemic attack [21,22]. Due to mecha-
nistic differences in their mode of action, febuxostat is known to have superior effects on XO
inhibition and SUA reduction than allopurinol [9]. Furthermore, febuxostat is expected to
exert superior anti-oxidative and anti-atherogenic activities [11], suggesting that febuxostat
may have more benefit in the treatment of CVD than allopurinol. Although allopurinol was
not used in the present study, febuxostat treatment for 24 months was at least not superior to
non-pharmacological care for suppressing carotid atherosclerosis progression, despite the
obvious urate-lowering effect of febuxostat.
Febuxostat and CVD
Several previous studies investigated whether pharmacological urate-lowering therapy in
patients with gout could improve cardiovascular outcomes, and the results were controversial
[13,23,24]. A systematic review and meta-analysis using data based on conventional adverse-
event reporting demonstrated that the clinical impact of febuxostat on the incidence of CVD
was neutral compared with allopurinol or placebo, whereas there was an increased incidence
of cardiovascular death with febuxostat treatment [25]. A large-scale cohort study also demon-
strated no difference in the risk of CVD between febuxostat and allopurinol, but there was a
trend towards an increased risk for all-cause mortality with long-term use of febuxostat [26].
In the CARES trial, conducted as a Food and Drug Administration (FDA) requirement for the
evaluation of febuxostat safety, febuxostat did not increase or decrease the incidence of CVD
Table 2. (Continued)
Endpoint Time point Febuxostat Control Group difference (95% CI) P Value
Number Mean (SD) Number Mean (SD)
Delta from baseline, mm 12 months 85 1.153 (4.695) 91 1.271 (6.235) −0.117 (−1.753 to 1.519) 0.89
24 months 79 1.133 (5.200) 89 0.954 (4.653) 0.179 (−1.332 to 1.691) 0.82
Percentage change from baseline 12 months 85 0.526 (1.281) 91 0.586 (1.702) −0.060 (−0.506 to 0.387) 0.79
24 months 79 0.526 (1.812) 89 0.338 (0.996) 0.188 (−0.267 to 0.642) 0.42
Plaque grayscale median Baseline 203 46.732 (25.870) 194 46.339 (25.232) 0.393 (−4.650 to 5.436) 0.88
12 months 85 54.648 (24.738) 91 54.503 (25.045) 0.145 (−7.264 to 7.554) 0.97
24 months 79 54.145 (26.906) 89 52.451 (19.897) 1.694 (−5.599 to 8.987) 0.65
Delta from baseline, mm 12 months 85 3.332 (26.636) 91 9.810 (26.446) −6.478 (−14.381 to 1.425) 0.11
24 months 79 2.608 (30.699) 89 8.838 (21.664) −6.231 (−14.432 to 1.970) 0.14
Percentage change from baseline 12 months 85 0.331 (1.326) 91 0.443 (0.759) −0.112 (−0.437 to 0.214) 0.50
24 months 79 0.226 (0.722) 89 0.486 (0.994) −0.260 (−0.523 to 0.002) 0.052
Abbreviations: CCA, common carotid artery; CI, confidence interval; ICA, internal carotid artery; IMT, intima-media thickness; SD, standard deviation
https://doi.org/10.1371/journal.pmed.1003095.t002
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relative to allopurinol, although there were significant increases in the incidence of cardiovas-
cular and all-cause deaths in the febuxostat arm [12]. Thus, no study has shown a superior or
inferior effect of febuxostat on the risk of atherosclerotic CVD, and this may partly support
our findings.
A previous cohort study in a Japanese population without comorbidities demonstrated that
asymptomatic hyperuricemia was associated with the development of cardiometabolic disease
[3]. The Japanese guideline for the management of hyperuricemia and gout officially allows
the use of pharmacological urate-lowering drugs in asymptomatic hyperuricemia [27], and
this is different from the relevant guidelines in the United States and Europe [28,29]. In partic-
ular, the use of urate-lowering agents in asymptomatic hyperuricemia is allowed in patients
with non-gout comorbidities, such as hypertension, diabetes, renal impairment, and CVD. In
our study, most patients had such comorbidities at baseline but did not have active gout. In
addition, their baseline SUA levels and the values of mean CCA-IMT at baseline were relatively
low. Our findings suggest that febuxostat treatment for 24 months was not associated with an
obvious anti-atherosclerotic effect, at least in the overall population studied. However, because
subgroup analysis showed a tendency for febuxostat treatment in patients with SUA�8.0 mg/
dL to delay CCA-IMT progression relative to non-pharmacological care for hyperuricemia,
the effect of febuxostat on atherosclerosis may differ among patients with hyperuricemia
Fig 2. Subgroup analyses of percentage change from baseline to 24 months in the mean CCA-IMT. This shows the point estimate
of the mean difference between the treatment groups (febuxostat − control) for the primary endpoint, stratified according to
subgroups of the allocation and prespecified factors. The error bars represent the 95% CI. ASCVD, atherosclerotic cardiovascular
disease; BMI, body mass index; CCA, common carotid artery; CI, confidence interval; eGFR, estimated glomerular filtration rate;
IMT, intima-media thickness.
https://doi.org/10.1371/journal.pmed.1003095.g002
Fig 3. Changes in SUA. The values are expressed as means, with the error bars showing the SDs. (A) Changes in mean SUA. The mean values of SUA were lower in the
febuxostat group at 6 months (febuxostat, 5.14 [SD 1.26] mg/dL versus control, 7.43 [SD 1.14] mg/dL; mean between-group difference [febuxostat − control] −2.28 mg/
dL [95% CI −2.50 to −2.06 mg/dL ]; P< 0.001), 12 months (febuxostat: 5.06 [SD 1.32] mg/dL versus control, 7.31 [SD 0.99] mg/dL; mean between-group difference
−2.25 mg/dL [95% CI −2.47 to −2.03 mg/dL]; P< 0.001), and 24 months (febuxostat, 4.66 [SD 1.27] mg/dL versus control, 7.28 [SD 1.27] mg/dL; mean between-group
difference −2.62 mg/dL [95% CI −2.86 to −2.38 mg/dL]; P< 0.001). (B) Absolute changes in SUA. The mean between-group differences in the absolute change in SUA
from baseline were also significant at 6 months (−2.31 mg/dL [95% CI −2.55 to −2.08 mg/dL]; P< 0.001), 12 months (−2.31 mg/dL [95% CI −2.56 to −2.06 mg/dL];
P< 0.001), and 24 months (−2.65 mg/dL [95% CI −2.93 to −2.37 mg/dL]; P< 0.001). CI, confidence interval; SD, standard deviation; SUA, serum uric acid.
https://doi.org/10.1371/journal.pmed.1003095.g003
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according to the levels of SUA and be clinically beneficial in patients with higher SUA. In addi-
tion, we observed a trend of attenuated progression of carotid atherosclerosis in the subgroup
of patients on febuxostat with less advanced carotid lesions, although this improvement was
not statistically significant. This result raises the possibility that febuxostat was effective for
attenuating earlier progression of carotid atherosclerosis, suggesting a limited role of febuxo-
stat on the development of atherosclerosis. Further research is therefore warranted to deter-
mine the optimal patients with asymptomatic hyperuricemia who could potentially obtain
cardiovascular and renal benefits from treatment with febuxostat [30].
Considering recent randomized trials with febuxostat in Japan, the FREED study showed
that febuxostat reduced the risk of composite clinical events relative to non-febuxostat therapy
in asymptomatic hyperuricemia, and that was largely driven by delaying the progression of
renal dysfunction [31]. In the FEATHER study, febuxostat did not slow the decline of renal
function compared with placebo in asymptomatic hyperuricemia and stage 3 chronic kidney
disease [32]. In both studies, the incidence of cerebral and cardiovascular events was compara-
ble between the treatment groups in asymptomatic hyperuricemia. Given the results of those
studies and our findings, it may not be reasonable to use febuxostat to mitigate atherogenesis
and subsequent CVD, at least in the overall population with asymptomatic hyperuricemia.
However, febuxostat-mediated suppression of gout arthritis and renal impairment may
improve quality of life and future prognosis in asymptomatic hyperuricemia [31,32]. Impor-
tantly, febuxostat treatment in Japanese patients with asymptomatic hyperuricemia did not
show increased mortality in these randomized trials.
Study limitations
This study has several limitations. First, this was an open-label study rather than a double-
blind placebo-controlled trial, and the outcome might have been biased from the investigators’
choice of care. To minimize this possibility, all endpoints for carotid IMT were evaluated auto-
matically in a blinded manner at a central core laboratory. Second, the actual dropout rate was
higher than that originally estimated, and therefore the sample size might have been too small
to detect a robust treatment effect on carotid IMT. Furthermore, the treatment period (24
months) might have been too short. Third, as in the recent randomized trials in Japanese
[31,32], patients with symptomatic hyperuricemia were excluded from enrollment. This is the
most striking difference between our study and other studies performed in regions other than
Japan. In addition, the baseline SUA levels in our study were relatively low (7.7 mg/dL). There-
fore, it may not be possible to generalize our findings to symptomatic hyperuricemia or to
other ethnic groups. We also did not compare the effect of febuxostat with conventional allo-
purinol. Fourth, the values of mean CCA-IMT were relatively low despite the inclusion of
Table 3. Number of patients with adjudicated clinical events.
Adjudicated clinical event Febuxostat (n = 241) Control (n = 247)
Total, number (%) 9 (3.7) 16 (6.5)
Cardiovascular death 1 (0.4) 3 (1.2)
Nonfatal myocardial infarction 0 (0.0) 1 (0.4)
Nonfatal stroke 3 (1.2) 5 (2.0)
Composite renal eventsa 3 (1.2) 4 (1.6)
Non-cardiovascular death 2 (0.8) 4 (1.6)
All-cause death 3 (1.2) 7 (2.8)
aComposite of doubling of serum creatinine, initiation of hemodialysis, and renal transplantation.
https://doi.org/10.1371/journal.pmed.1003095.t003
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patients with a maximum CCA-IMT�1.1 mm, which indicates carotid arterial plaque [15].
Such a finding has recently been shown to be a significant risk factor for future CVD in the
general Japanese population [33]. This suggests that it would have been difficult to decrease
these values further using the study intervention, possibly affecting, in part, the IMTs mea-
sured in the study. Moreover, there is evidence that the cardiovascular risk factors, hyperten-
sion and hypercholesterolemia, have different effects on the two components (i.e., the intima
and media) of the IMT in pig carotid arteries [34]. It is therefore possible that hyperuricemia
and XO inhibitors may have similar effects. However, because current carotid ultrasonography
techniques used in the clinical setting are not able to measure these two components sepa-
rately, it was not possible to determine which component was more affected in our study.
Fifth, the change in scores used as primary and secondary endpoints in this study could have
occurred as a result of either deleting missing data, ignoring the third time point, or as a conse-
quence of measurement errors. Because the same patients were measured multiple times dur-
ing the study, a better method than ANCOVA might be needed in order to take into account
the effect of those errors. Lastly, different dosages of febuxostat were used in the febuxostat
arm. The final doses of febuxostat were lower than expected, with one third of the study partic-
ipants remaining on 10 mg of febuxostat after 24 months. It was therefore not possible to assess
any vascular benefits of febuxostat per se, independent of the urate-lowering effect. Further
research is therefore needed to determine the effects of febuxostat on atherosclerosis and car-
diovascular safety in patients with hyperuricemia irrespective of gout.
In conclusion, in Japanese patients with asymptomatic hyperuricemia, 24 months of
febuxostat treatment had no obvious effect on carotid atherosclerosis progression, compared
with non-pharmacological lifestyle modification. These findings do not support the use of
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